Andrea Perrone
Philadelphia,PA
Summary
Dynamic leader with extensive experience at Merck Pharmaceuticals, excelling in financial management and metrics-driven risk management. Achieved significant savings through strategic resource allocation and integration leadership. Proven track record in regulatory compliance and fostering patient engagement, enhancing clinical trial outcomes across diverse therapeutic areas. During her tenure at Merck, she has supported over 100 approvals across all three therapeutic areas.
Overview
19
19
years of professional experience
1
1
Certification
Work History
VP, Clinical Study Management, Imaging & Path
Merck Pharmaceuticals
North Wales, PA
01.2024 - Current
- Oversaw financial operations, managing $30 million budget for 1,200 staff and $2.5 million travel budget.
- Strategic oversight on headcount forecasting for 2025, and sharing of resources across three therapeutic areas, achieving savings of approximately $9.5 million.
- Executive Sponsor for the initiative to gather site and patient input for protocol design in compliance with new FDA guidance.
- Launched Power Automate app to enhance communication between sites and sponsors.
- Developed a tool to track early risk and mitigation efforts, along with metrics and goals tracking.
- 2024 Portfolio - 285 active studies, 19,000+ active sites, and approximately 76,000 active patients across all three therapeutic areas. 93% (500/538) GCTO milestones achieved on time.
- Appointed by the President of MRL to lead integration for the asset acquisition of Curon, CN201, a novel bispecific antibody for the treatment of B-cell-associated diseases in autoimmune and oncology (9 August 2024).
Associate VP, Clinical Study Management
Merck Pharmaceuticals
North Wales, PA
03.2019 - 01.2024
- Oversaw financial operations for team of 850 people.
- In 2023 Oversight of oncology portfolio 210 active trials, 15,000 active sites and 39,000 active subjects. 39 new studies; 31 assets.
- Key collaborations: 10 with AZ, 16 Eisai, 20 SeaGen, 144 with Kelun, 6 with Moderna
- Achieved greater than 93% metrics across GCTO on time.
- Appointed by the President of MRL to lead integration for the Imago Biosciences acquisition (January 11, 2023). It entailed six trials to integrate: one in Phase 1, three in Phase 2, and two in Phase 50+ person organization with a talent harmonization and retention model.
- Directly supported meetings across global Clinical Site Partners to share early insights and engagement in the oncology pipeline.
Associate Vice President, Head of Clinical Imaging
Merck Pharmaceuticals
West Point, PA
01.2017 - 02.2025
- Established core principles, Key Performance Indicators and metrics for independent imaging core labs supporting oncology trial endpoints in collaboration with Merck's Portfolio and Relationship Management team.
- Developed resources and job aids to define roles of clinical imaging scientists and leads.
- Built a team of 11 professionals to enhance clinical imaging across all therapeutic areas at Merck.
- Provided regulatory support for Keytruda filings for EMA sponsor inspections and meetings with the FDA (Keynote 001, 002, and 006).
Executive Director
Merck Pharmaceuticals
West Point, PA
09.2012 - 01.2019
- Individual contributor within the Translational Medicine team as the sole radiologist.
- Leveraged experience working with an imaging Core Lab to establish best practices to be a "Sponsor of Choice"
- Developed a novel imaging criteria, 'iRECIST' along with the RECIST Working Group and presented at > 75 Investigator Meetings to enable 'treatment beyond radiographic progression'.
Head of Late Clinical Development
General Electric Healthcare
Princeton, NJ
04.2011 - 09.2012
- Directed clinical oversight for development of CT and MRI diagnostic contrast agents.
VP, Global Clinical Operations
BioClinica (now called Clario)
Princeton, NJ
04.2006 - 04.2011
- Delivered operational and clinical oversight for pharmaceutical and biotechnology clients conducting imaging-focused clinical trials.
- Provided regulatory guidance across Phase 1-4 trials in oncology, musculoskeletal, neurology, rheumatology, and cardiology.
- Facilitated compliance with industry regulations to ensure trial integrity and safety.
Education
M.D. - 4 year Radiology Residency
University of Pittsburgh
Pittsburgh, PA07-1999
Some College (No Degree) - 1 Year Transitional Internship At Fairfax Hospital
Georgetown School of Medicine
Fairfax, VA06-1995
M.D. - 4 Year Medical School
Georgetown University
Washington, DC06-1994
Bachelor of Science - Finance
University of Maryland
College Park, MD12-1987
Skills
- Financial management
- Metrics and Risk Management
- People Leadership
- Regulatory compliance and inspection support (interviewed by the EMA for the Keytruda sponsor inspection and FDA meetings in 2014)
- Integration leadership requires leadership across an enterprise team of 12 corporate functions, tracking timelines, metrics, and communications to the executive suite
- Process Improvement: launching MS Copilot and Center of Excellence
- Patient/Site Engagement: via Clinical Site Partnerships and tools to streamline
Certification
- Association of Clinical Research Professionals (ACRP) December 2024
- California Medical License- retired
- Johns Hopkins Management Program 2017
- Harvard Build the Best Teams Program (Perlmutter) 2016
- Wharton Management and Engagement Foundations 2015
- Coaching Conversations/Change Acceleration GE Healthcare 2011
Accomplishments
- Division Award from Joe Milletich for contributions to MK3475 2015, 2017, 2018
- Division Award from Rupert Vessey for contributions to Keytruda Approval 2014
- Special Achievement from Frank Clyburn in support of ASCO 2014
- Special Achievement from Roger Perlmutter in support of PD-L1 2013
Affiliations
- Steering Committee for Senior Women's Leaders (2024-2025
- Steering Committee for Oncology Women Leaders (OWL) 2019- 2024
- RECIST Working Group October 2016- 2018
- American Society of Clinical Oncology 2012 - 2019
- Quantitative Imaging Biomarker Alliance 2012- 2014
References
References available upon request.
Timeline
VP, Clinical Study Management, Imaging & Path
Merck Pharmaceuticals
01.2024 - Current
Associate VP, Clinical Study Management
Merck Pharmaceuticals
03.2019 - 01.2024
Associate Vice President, Head of Clinical Imaging
Merck Pharmaceuticals
01.2017 - 02.2025
Executive Director
Merck Pharmaceuticals
09.2012 - 01.2019
Head of Late Clinical Development
General Electric Healthcare
04.2011 - 09.2012
VP, Global Clinical Operations
BioClinica (now called Clario)
04.2006 - 04.2011
M.D. - 4 year Radiology Residency
University of Pittsburgh
Some College (No Degree) - 1 Year Transitional Internship At Fairfax Hospital
Georgetown School of Medicine
M.D. - 4 Year Medical School
Georgetown University
Bachelor of Science - Finance
University of Maryland
Similar Profiles
Ernest SalamoneErnest Salamone
Maintenance Technician at Merck PharmaceuticalsMaintenance Technician at Merck Pharmaceuticals
Chrison JamesChrison James
Bio-Technician II at Merck PharmaceuticalsBio-Technician II at Merck Pharmaceuticals
Caroline OmariCaroline Omari
Senior Associate Technician at Merck PharmaceuticalsSenior Associate Technician at Merck Pharmaceuticals
Wendy LiroffWendy Liroff
People Manager at Gerson Lehrman Group, GLGPeople Manager at Gerson Lehrman Group, GLG
Noah ArtisNoah Artis
Summer Intern at City of PhiladelphiaSummer Intern at City of Philadelphia